Wall Street analysts expect SQZ Biotechnologies (NYSE:SQZ – Get Rating) to report earnings per share (EPS) of $0.67 for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for SQZ Biotechnologies’ earnings. The lowest EPS estimate is ($0.73) and the highest is ($0.60). The company is expected to publish its next earnings report on Thursday, March 17th.
On average, analysts expect SQZ Biotechnologies to report full year earnings per share for the current fiscal year of ($2.74) with EPS estimates ranging from ($2.81) to ($2.68). For the next fiscal year, analysts are forecasting that the company will report earnings per share of ($2.84) with EPS estimates ranging from ($4.06) to ($2.12). Zacks Investment Research EPS averages are an average based on a survey of research firms covering SQZ Biotechnologies.
Separately, on Sunday, December 12, BTIG Research issued a new research report with a “buy” rating and a price target of $40.00 on shares of SQZ Biotechnologies.
SQZ Biotechnologies shares opened at $5.28 on Friday. The company has a 50-day moving average price of $7.79 and a 200-day moving average price of $11.20. SQZ Biotechnologies has a 12-month low of $4.64 and a 12-month high of $16.23.
In related news, Director Amy W. Schulman bought 3,700 shares of the company’s stock in a transaction on Monday, December 13. The shares were acquired at an average price of $10.91 per share for a total transaction of $40,367.00. The transaction was disclosed in a filing with the SEC, which can be accessed at this link. Company insiders own 18.00% of the Company’s stock.
Several institutional investors recently changed their holdings in the company. NanoDimension Inc. acquired a new interest in SQZ Biotechnologies stock valued at approximately $12,906,000 during the fourth quarter. BlackRock Inc. increased its stake in SQZ Biotechnologies by 13.1% in the fourth quarter. BlackRock Inc. now owns 1,413,870 shares of the Company, valued at $12,625,000, having purchased an additional 163,780 shares during the period. Goldman Sachs Group Inc. increased its stake in SQZ Biotechnologies by 24.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 43,439 shares of the company’s stock, valued at $388,000, having purchased an additional 8,449 shares during this period. Virtu Financial LLC acquired a new interest in SQZ Biotechnologies for approximately $112,000 during the fourth quarter. Finally, 683 Capital Management LLC increased its stake in SQZ Biotechnologies by 9.4% during the fourth quarter. 683 Capital Management LLC now owns 1,852,135 shares of the Company’s stock valued at $16,540,000, having purchased an additional 159,748 shares during this period. Institutional investors and hedge funds own 48.84% of the company’s shares.
About SQZ Biotechnologies (received rating)
SQZ Biotechnologies Company, a clinical-stage biotechnology company, is developing transformative cell therapies for patients suffering from cancer, infectious diseases and other serious diseases. Its lead product candidate is SQZ-PBMC-HPV from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical , head and neck, anal, penile, vulva and vaginal cancer.
Get a Free Copy of the Zacks Research Report on SQZ Biotechnologies (SQZ)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide readers with the fastest, most accurate reporting. This story was reviewed by the MarketBeat editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should You Invest $1,000 in SQZ Biotechnologies Now?
Hear this before you consider SQZ Biotechnologies.
MarketBeat tracks Wall Street’s best-in-class, top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes hold… and SQZ Biotechnologies wasn’t on the list.
While SQZ Biotechnologies is currently rated a Buy by analysts, top analysts believe these five stocks are better buys.
Check out the 5 stocks here